Evidence map›Paper›PMID 26796959›Full record

ArticleBiological research2016

Reprimo as a modulator of cell migration and invasion in the MDA-MB-231 breast cancer cell line.

Kurt Buchegger, Carmen Ili, Ismael Riquelme, Pablo Letelier, Alejandro H Corvalán, Priscilla Brebi, Tim Hui-Ming Huang, Juan Carlos Roa

Open access · goldAbstract read
In one paragraph

Article in Biological research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Extrinsic induction of apoptosis and tumor suppression via the p53-Reprimo-Hippo-YAP/TAZ-p73 pathway.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Kurt BucheggerDepartment of Pathology, Molecular Pathology Laboratory BIOREN-CEGIN, School of Medicine, Universidad de La Frontera, Temuco, Chile. k.buchegger@gmail.com.
Carmen IliDepartment of Pathology, Molecular Pathology Laboratory BIOREN-CEGIN, School of Medicine, Universidad de La Frontera, Temuco, Chile. carmengloriaili@gmail.com.
Ismael RiquelmeDepartment of Pathology, Molecular Pathology Laboratory BIOREN-CEGIN, School of Medicine, Universidad de La Frontera, Temuco, Chile. 83ismode@gmail.com.
Pablo LetelierSchool of Health Sciences, Universidad Católica de Temuco, Temuco, Chile. pablolete@gmail.com.
Alejandro H CorvalánCentre for Translational Research in Oncology (CITO) and Department of Hematology and Oncology, Pontificia Universidad Catolica de Chile, Santiago, Chile. corvalan01@gmail.com.
Priscilla BrebiDepartment of Pathology, Molecular Pathology Laboratory BIOREN-CEGIN, School of Medicine, Universidad de La Frontera, Temuco, Chile. brebimieville@gmail.com.
Tim Hui-Ming HuangDepartment of Molecular Medicine/Institute of Biotechnology, University of Texas Health Science Center at San Antonio, STRF, Room 225, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA. huangt3@uthscsa.edu.
Juan Carlos RoaDepartment of Pathology, Advanced Center for Chronic Diseases (ACCDiS) (CITO), School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. jcroas@gmail.com.
Universidad de La Frontera · CLPontificia Universidad Católica de Chile · CLTemuco Catholic University · CLThe University of Texas Health Science Center at San Antonio · US

Funding

Predicting Drug Resistance in Cancer Genomes by DMA Methylation ProfilingU54CA113001 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HUANG, TIM H.-M. · 2004 to 2014
$16.1M
NCI NIH HHS U54 CA113001
6 · The paper itself

Abstract

backgroundReprimo (RPRM), a highly glycosylated protein, is a new downstream effector of p53-induced cell cycle arrest at the G2/M checkpoint, and a putative tumor suppressor gene frequently silenced via methylation of its promoter region in several malignances. The aim of this study was to characterize the epigenetic inactivation and its biological function in BC cell lines.

methodsThe correlation between RPRM methylation and loss of mRNA expression was assessed in six breast cancer cell lines by methylation specific PCR (MSP), 5'-Aza-2'-deoxycytidine treatment and RT-PCR assays. MDA-MB-231 cells were chosen to investigate the phenotypic effect of RPRM in cell proliferation, cell cycle, cell death, cell migration and invasion.

resultsIn the cancer methylome system (CMS) (web-based system for visualizing and analyzing genome-wide methylation data of human cancers), the CpG island region of RPRM (1.1 kb) was hypermethylated in breast cancer compared to normal breast tissue; more interesting still was that ERα(+) tumors showed higher methylation intensity than ERα(-). Downregulation of RPRM mRNA by methylation was confirmed in MDA-MB-231 and BT-20 cell lines. In addition, overexpression of RPRM in MDA-MB-231 cells resulted in decreased rates of cell migration, wound healing and invasion in vitro. However, RPRM overexpression did not alter cell viability, phosphatidylserine (PS) translocation or G2/M cell cycle transition.

conclusionTaken together, these data suggest that RPRM is involved in decreased cell migration and invasion in vitro, acting as a potential tumor suppressor gene in the MDA-MB-231 cell line.

Indexed as

Analysis of VarianceBlotting, WesternBreast NeoplasmsCell CycleCell Cycle ProteinsCell Line, TumorCell MovementCell ProliferationCell SurvivalDNA MethylationEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticGlycoproteinsHumansNeoplasm InvasivenessCell Cycle ProteinsGlycoproteinsRPRM protein, human

Identifiers

PMID26796959
PMCPMC4722741
OpenAlexW2275066906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.